LE WE PMID CA
Mammary gland (Neoplasia)423Brustdruese (Neubildung)

AIB1

AMP activated protein kinase

Anastrozole

Antineoplastic agents (Novel target ideas)

Aromatase Inhibitor

Arzoxifene ttSERM

ATM

Bisphosphonates

Bone (Metastasis)

BRCA

BRCA1

BRCA2

BRIP1

Bruxism

Calphostin C

Capecitabine

Carcinosarcoma

Cdh1

CHEK2

Chemoprevention

CNS (Metastasis)

Colon and rectum (Neoplasia)

COX2

CYP19A1 Aromatase

DNA (Repair and Toxicology)

Docetaxel

Endocrine disruptor

Epigenetics

Epirubicin

Epithelio mesenchymal transition

Exemestane

Fura2

Growth hormone

Gynecomastia

IGF1

Interleukin24 MDA7

Ixabepilone

KLF

Klf4

KLF5

KLF6

KLF9

Laboratory medicine

Lapatinib

Letrozole

LKB1

Lymph node (Metastasis and sentinel)

Mammary gland (Development)

Mammary gland (Imaging)

Mammary gland (Involution)

Mammary gland (Metastasis)

Mammary gland (MRT)

Mammary gland (Neoplasia)

Mammary gland (Sonography)

Matrix producing carcinoma of the breast

MET

Metformin

Microendoscopy

Mouse mammary tumor virus

MRT (functional fMRT)

Myofibroblastoma

Natural products

NBS1

Neoplasia (Carcinogenesis)

Neoplasia (Dormancy)

Neoplasia (Inherited)

Neoplasia (Invasion and metastasis)

Neoplasia (Oncofetal antigens)

Neoplasia (Oncolytic virus)

Neoplasia (Tumor biology and immunology)

Notch

Osteoporosis

Ovary (Neoplasia)

P53

Paclitaxel

PALB2

PARP

PGRMC1

Preventive surgery

Protein kinase B Akt

Protein kinase C

PTEN MMAC1 TEP1

Rad50

Radiopharmacology

Receptor (EGF)

Receptor (Estrogen)

Receptor (Leptin)

Receptor (Progesterone)

SLC39A6

SNAIL

Stem cell (Neoplasia)

Steroid sulfatase

Tamoxifen

TGF beta

Tpl2 Cot

Transporter (Zinc)

Trastuzumab ttHER2

TRPC1

TRPC6

TRPM7

TRPM8

TRPV6

Twist

UFT

Uterus (Neoplasia)

Vitamin D

Wnt beta Catenin TCF

Zinc

1990  
1
Carcinoma of the male breast: a review of 41 cases.
[1699287] South Med J 83(10): 1162-7 (1990)
2008  
2
Hereditary breast and ovarian cancers.
[19074707] Can Fam Physician 54(12): 1691-2 (2008)
2002  
3
Radiation treatment for breast cancer. Recent advances.
[12113193] Can Fam Physician 48(-): 1065-9 (2002)
2010  
4
Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.
[20204119] Dtsch Arztebl Int 107(6): 85-91 (2010)
2007  
5
Breast cancer (non-metastatic).
[19450345] Clin Evid (Online) 2007(): (2007)
2009  
6
HER2 breast cancer therapies: a review.
[19707416] Biologics 3(): 289-301 (2009)
2008  
7
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.
[19707381] Biologics 2(3): 505-15 (2008)
2007  
8
Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.
[19707333] Biologics 1(3): 229-39 (2007)
2007  
9
Trastuzumab in the management of early and advanced stage breast cancer.
[19707345] Biologics 1(1): 19-31 (2007)
2008  
10
Exemestane in early breast cancer: a review.
[19337436] Ther Clin Risk Manag 4(6): 1295-304 (2008)
2008  
11
Long-term safety of aromatase inhibitors in the treatment of breast cancer.
[18728707] Ther Clin Risk Manag 4(1): 189-204 (2008)
2007  
12
A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.
[18472989] Ther Clin Risk Manag 3(4): 665-73 (2007)
2009  
13
The use of paclitaxel in the management of early stage breast cancer.
[19567209] Health Technol Assess 13 Suppl 1(): 15-22 (2009)
2009  
14
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
[19567208] Health Technol Assess 13 Suppl 1(): 7-13 (2009)
2009  
15
Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
[19567207] Health Technol Assess 13 Suppl 1(): 1-6 (2009)
2007  
16
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
[17903394] Health Technol Assess 11(40): 1-144 (2007)
2007  
17
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
[17610808] Health Technol Assess 11(26): iii-iv, ix-xi, 1-134 (2007)
2006  
18
Papillary carcinoma in a male breast cyst: a diagnostic challenge.
[17002839] Ann R Coll Surg Engl 88(5): W3-5 (2006)
1995  
19
Management of ductal carcinoma in situ of the breast.
[7598411] Ann R Coll Surg Engl 77(3): 163-7 (1995)
1954  
20
Carcinoma of the breast: a review of the treatment.
[13149066] Ann R Coll Surg Engl 14(4): 215-46 (1954)
2004  
21
Axillary lymph node dissection versus the sentinel lymph node technique in breast cancer.
[15213611] Ann Surg 240(1): 7-8 (2004)
1998  
22
Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.
[9605656] Ann Surg 227(5): 645-51; discussion 651-3 (1998)
1994  
23
Current management of carcinoma of the breast.
[8053734] Ann Surg 220(2): 121-36 (1994)
1992  
24
Current management of male breast cancer. A review of 104 cases.
[1319699] Ann Surg 215(5): 451-7; discussion 457-9 (1992)
1987  
25
Adenoid cystic carcinoma of the breast. Data from the Connecticut Tumor Registry and a review of the literature.
[3030200] Ann Surg 205(3): 295-301 (1987)
1985  
26
Sarcoma of the breast. A study of 32 patients with reappraisal of classification and therapy.
[3977455] Ann Surg 201(4): 527-32 (1985)
1964  
27
PAGET'S DISEASE OF THE MALE BREAST: A CASE REPORT AND A REVIEW OF THE LITERATURE.
[14119196] Ann Surg 159(-): 305-9 (1964)
1951  
28
The rationale of radical mastectomy; a review.
[14819967] Ann Surg 133(3): 330-43 (1951)
2009  
29
Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients.
[19356240] BMC Cancer 9(): 108 (2009)
2006  
30
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
[17116247] BMC Cancer 6(): 269 (2006)
2006  
31
Evidence-based risk factors for seroma formation in breast surgery.
[16684859] Jpn J Clin Oncol 36(4): 197-206 (2006)
2010  
32
Chemotherapy for breast cancer (Review).
[20878101] Oncol Rep 24(5): 1121-31 (2010)
2010  
33
Male breast cancer: risk factors, diagnosis, and management (Review).
[20878100] Oncol Rep 24(5): 1115-20 (2010)
2008  
34
Clinical characteristics of small cell carcinoma of the breast.
[18357385] Oncol Rep 19(4): 981-5 (2008)
2009  
35
Optimal use of taxanes in metastatic breast cancer.
[19526080] Curr Oncol 16(3): 8-20 (2009)
2004  
36
Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response.
[15335458] Clin Breast Cancer 5(3): 235-8 (2004)
2002  
37
Bisphosphonates: biological response modifiers in breast cancer.
[12196279] Clin Breast Cancer 3(3): 206-16; discussion 217-8 (2002)
2001  
38
Platinum compounds in the treatment of advanced breast cancer.
[11899413] Clin Breast Cancer 2(3): 190-208; discussion 209 (2001)
2009  
39
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.
[19254941] Ann Oncol 20(4): 615-20 (2009)
2008  
40
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
[18480068] Ann Oncol 19(9): 1530-9 (2008)
2008  
41
Recent advances in adjuvant systemic therapy for early-stage breast cancer.
[18611869] Ann Oncol 19 Suppl 5(): v122-7 (2008)
2008  
42
The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients.
[18407953] Ann Oncol 19(7): 1213-5 (2008)
2008  
43
Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456775] Ann Oncol 19 Suppl 2(): ii7-10 (2008)
2008  
44
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456744] Ann Oncol 19 Suppl 2(): ii11-3 (2008)
2007  
45
A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.
[17264064] Ann Oncol 18(7): 1152-8 (2007)
2007  
46
2007  
47
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
[17229773] Ann Oncol 18(6): 977-84 (2007)
2006  
48
Precancerous lesions of the breast.
[17018737] Ann Oncol 17 Suppl 10(): x271-3 (2006)
2005  
49
Chemotherapy for metastatic breast cancer.
[15923425] Ann Oncol 16 Suppl 4(): iv23-27 (2005)
2004  
50
Primary chemotherapy for breast cancer: the evidence and the future.
[15277254] Ann Oncol 15(8): 1161-71 (2004)
2003  
51
The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
[12702519] Ann Oncol 14(5): 667-74 (2003)
1967  
52
A review of 146 cases of carcinoma of the breast operated on between 1930 and 1943.
[6028079] Br J Cancer 21(2): 260-9 (1967)
2005  
53
A systematic review of taxane-containing regimens for metastatic breast cancer.
[16052223] Br J Cancer 93(3): 293-301 (2005)
2009  
54
New molecular classifications of breast cancer.
[19729680] CA Cancer J Clin 59(5): 303-13 (2009)
2000  
55
The diagnosis and management of ductal carcinoma in-situ of the breast.
[10901741] CA Cancer J Clin 50(3): 184-200 (2000)
1998  
56
Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology.
[9522825] CA Cancer J Clin 48(2): 108-28 (1998)
1998  
57
Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology.
[9522824] CA Cancer J Clin 48(2): 83-107 (1998)
1997  
58
Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast.
[8996078] CA Cancer J Clin 47(1): 52-64 (1997)
1997  
59
Tumor-related prognostic factors for breast cancer.
[8996077] CA Cancer J Clin 47(1): 28-51 (1997)
1995  
60
The surgical management of primary invasive breast cancer.
[7656131] CA Cancer J Clin 45(5): 279-88 (1995)
1995  
61
The woman at increased risk for breast cancer: evaluation and management strategies.
[7656130] CA Cancer J Clin 45(5): 263-78 (1995)
1995  
62
Management of ductal carcinoma in situ.
[7600280] CA Cancer J Clin 45(4): 244-53 (1995)
1995  
63
Primary chemotherapy in surgically resectable breast cancer.
[7600279] CA Cancer J Clin 45(4): 227-43 (1995)
1995  
64
Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy.
[7600278] CA Cancer J Clin 45(4): 199-226 (1995)
1991  
65
1991  
66
The role of radiation therapy in the management of primary breast cancer.
[1900035] CA Cancer J Clin 41(2): 85-96 (1991)
1991  
67
The surgical management of primary breast cancer.
[1900034] CA Cancer J Clin 41(2): 71-84 (1991)
2008  
68
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
[18819158] Cancer 113(9): 2385-97 (2008)
2008  
69
The molecular journey from ductal carcinoma in situ to invasive breast cancer.
[18383519] Cancer 112(10): 2130-42 (2008)
2007  
70
Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
[17722109] Cancer 110(8): 1687-96 (2007)
2007  
71
Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies.
[17647249] Cancer 110(6): 1187-94 (2007)
2005  
72
Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?
[16155942] Cancer 104(8): 1567-74 (2005)
2005  
73
Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.
[15770688] Cancer 103(9): 1778-84 (2005)
2005  
74
Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
[15637696] Cancer 103(4): 672-9 (2005)
2004  
75
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
[15378476] Cancer 101(7): 1482-9 (2004)
2004  
76
Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening.
[15042665] Cancer 100(7): 1337-44 (2004)
2000  
77
Pathologic analysis of sentinel lymph nodes in breast carcinoma.
[10699882] Cancer 88(5): 971-7 (2000)
1999  
78
Understanding ductal carcinoma in situ: a step in the right direction.
[10430242] Cancer 86(3): 375-7 (1999)
1999  
79
Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996.
[10091736] Cancer 85(3): 629-39 (1999)
1998  
80
Carcinoma of the breast in males: a multiinstitutional survey.
[9690543] Cancer 83(3): 498-509 (1998)
1998  
81
Metaplastic carcinoma of the breast: report of three cases.
[9506353] Cancer 82(6): 1082-7 (1998)
1997  
82
The role of histologic grading in the prognosis of patients with carcinoma of the breast: is this a neglected opportunity?
[9351538] Cancer 80(9): 1708-16 (1997)
2010  
83
A review of triple-negative breast cancer.
[20664514] Cancer Control 17(3): 173-6 (2010)
2001  
84
1999  
85
Ductal Carcinoma In Situ of the Breast.
[10758556] Cancer Control 6(3): 264-271 (1999)
2008  
86
Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
[18980963] Clin Cancer Res 14(21): 6725-9 (2008)
1998  
87
Update on endocrine therapy for breast cancer.
[9533518] Clin Cancer Res 4(3): 527-34 (1998)
2009  
88
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
[19657108] J Natl Cancer Inst 101(17): 1174-81 (2009)
2008  
89
Anthracyclines in the treatment of HER2-negative breast cancer.
[18159066] J Natl Cancer Inst 100(1): 2-4 (2008)
2009  
90
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
[19346299] Oncologist 14(4): 320-68 (2009)
2008  
91
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
[18849320] Oncologist 13(10): 1114-9 (2008)
2008  
92
Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.
[18586917] Oncologist 13(6): 620-30 (2008)
2008  
93
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
[18515736] Oncologist 13(5): 515-25 (2008)
2007  
94
Current treatment and clinical trial developments for ductal carcinoma in situ of the breast.
[18055847] Oncologist 12(11): 1276-87 (2007)
2007  
95
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
[17470679] Oncologist 12(4): 370-4 (2007)
2007  
96
BRCA1, a potential predictive biomarker in the treatment of breast cancer.
[17296808] Oncologist 12(2): 142-50 (2007)
2006  
97
Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
[16880231] Oncologist 11(7): 718-31 (2006)
2006  
98
Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
[16880230] Oncologist 11(7): 704-17 (2006)
2006  
99
Aromatase inhibitors in breast cancer: an overview.
[16794235] Oncologist 11(6): 553-62 (2006)
2006  
100
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
[16794234] Oncologist 11(6): 541-52 (2006)
2006  
101
Benign breast diseases: classification, diagnosis, and management.
[16720843] Oncologist 11(5): 435-49 (2006)
2006  
102
Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
[16971734] Oncologist 11 Suppl 1(): 4-12 (2006)
2005  
103
A review of the diagnosis and management of male breast cancer.
[16079314] Oncologist 10(7): 471-9 (2005)
2004  
104
Recognition and management of hereditary breast cancer syndromes.
[14755011] Oncologist 9(1): 13-24 (2004)
2003  
105
Update on the management of inflammatory breast cancer.
[12697939] Oncologist 8(2): 141-8 (2003)
1977  
106
Comparative effects of a series of prolactin inhibitors, 17beta-estradiol and 2alpha-methyldihydrotestosterone propionate, on growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas.
[409489] Cancer Res 37(11): 3932-8 (1977)
2010  
107
Histological types of breast cancer: how special are they?
[20452298] Mol Oncol 4(3): 192-208 (2010)
2005  
108
Aromatase inhibitors in the treatment of breast cancer.
[15814851] Endocr Rev 26(3): 331-45 (2005)
2008  
109
HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
[18480007] Am J Clin Pathol 129(6): 907-11 (2008)
2008  
110
HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
[18208807] Am J Clin Pathol 129(2): 263-73 (2008)
2007  
111
Breast cancer: origins and evolution.
[17975657] J Clin Invest 117(11): 3155-63 (2007)
2008  
112
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.
[18687797] J Mol Diagn 10(5): 383-95 (2008)
2007  
113
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
[17803883] Mayo Clin Proc 82(9): 1131-40 (2007)
2007  
114
A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis.
[17673070] Mayo Clin Proc 82(8): 999-1012 (2007)
2008  
115
Primary breast cancer in men: clinical, imaging, and pathologic findings in 57 patients.
[19020230] AJR Am J Roentgenol 191(6): 1631-9 (2008)
2008  
116
Spectrum of papillary lesions of the breast: clinical, imaging, and pathologic correlation.
[18716096] AJR Am J Roentgenol 191(3): 700-7 (2008)
2001  
117
Radioguided sentinel lymph node biopsy in breast cancer surgery.
[11483681] J Nucl Med 42(8): 1198-215 (2001)
2009  
118
From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation.
[19448124] Radiographics 29(3): 907-31 (2009)
2009  
119
Nipple-areolar complex: normal anatomy and benign and malignant processes.
[19325062] Radiographics 29(2): 509-23 (2009)
2008  
120
Rare breast lesions: correlation of imaging and histologic features with WHO classification.
[18794315] Radiographics 28(5): 1399-414 (2008)
2007  
121
Common and unusual diseases of the nipple-areolar complex.
[18180236] Radiographics 27 Suppl 1(): S65-77 (2007)
2007  
122
Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation.
[18180235] Radiographics 27 Suppl 1(): S53-64 (2007)
2007  
123
Breast lesions incidentally detected with CT: what the general radiologist needs to know.
[18180233] Radiographics 27 Suppl 1(): S37-51 (2007)
2007  
124
In vivo proton MR spectroscopy of the breast.
[18180231] Radiographics 27 Suppl 1(): S253-66 (2007)
2007  
125
Proton (1H) MR spectroscopy of the breast.
[18180230] Radiographics 27 Suppl 1(): S241-52 (2007)
2007  
126
FDG PET, PET/CT, and breast cancer imaging.
[18180228] Radiographics 27 Suppl 1(): S215-29 (2007)
2007  
127
FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations.
[18180227] Radiographics 27 Suppl 1(): S197-213 (2007)
2007  
128
Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation.
[18180225] Radiographics 27 Suppl 1(): S165-82 (2007)
2006  
129
Imaging characteristics of malignant lesions of the male breast.
[16844928] Radiographics 26(4): 993-1006 (2006)
2004  
130
Thoracic manifestations of breast cancer and its therapy.
[15371608] Radiographics 24(5): 1269-85 (2004)
2004  
131
Normal and abnormal US findings at the mastectomy site.
[15026586] Radiographics 24(2): 357-65 (2004)
2003  
132
Missed breast carcinoma: pitfalls and pearls.
[12853663] Radiographics 23(4): 881-95 (2003)
2002  
133
Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
[11796893] Radiographics 22(1): 5-17 (2002)
1998  
134
High-resolution MR imaging for the detection, diagnosis, and staging of breast cancer.
[9672975] Radiographics 18(4): 903-12 (1998)
1996  
135
Lessons from mammographic-histopathologic correlation of large-core needle breast biopsy.
[8888394] Radiographics 16(5): 1111-30 (1996)
1990  
136
Internal mammary lymphadenopathy: imaging of a vital lymphatic pathway in breast cancer.
[2217975] Radiographics 10(5): 857-70 (1990)
2010  
137
US of breast masses categorized as BI-RADS 3, 4, and 5: pictorial review of factors influencing clinical management.
[20833845] Radiographics 30(5): 1199-213 (2010)
2010  
138
Radiologic and pathologic findings in breast tumors with high signal intensity on T2-weighted MR images.
[20228333] Radiographics 30(2): 533-48 (2010)
1999  
139
Unusual breast lesions: radiologic-pathologic correlation.
[10517440] Radiographics 19 Spec No(-): S11-26; quiz S260 (1999)
2007  
140
Granular cell tumour of the breast: MRI findings and review of the literature.
[17940129] Br J Radiol 80(960): 970-4 (2007)
2007  
141
Mammary angiosarcomas: imaging findings in 24 patients.
[17325063] Radiology 242(3): 725-34 (2007)
2007  
142
Unusual breast cancers: useful clues to expanding the differential diagnosis.
[17325062] Radiology 242(3): 683-94 (2007)
2006  
143
Phyllodes tumor of the breast: correlation between MR findings and histologic grade.
[17032912] Radiology 241(3): 702-9 (2006)
2002  
144
Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases.
[12034956] Radiology 223(3): 829-38 (2002)
2001  
145
MR imaging of the breast for the detection, diagnosis, and staging of breast cancer.
[11425968] Radiology 220(1): 13-30 (2001)
2000  
146
Focal fibrosis of the breast: imaging characteristics and histopathologic correlation.
[10887257] Radiology 216(1): 255-9 (2000)
1999  
147
Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer.
[10352613] Radiology 211(3): 835-44 (1999)
1983  
148
Ultrasound, x-ray mammography, and histopathology of cystosarcoma phylloides.
[6294737] Radiology 146(2): 481-6 (1983)
2010  
149
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555111] Ann Oncol 21 Suppl 5(-): v9-14 (2010)
2010  
150
BRCA in breast cancer: ESMO Clinical Practice Guidelines.
[20555082] Ann Oncol 21 Suppl 5(-): v20-2 (2010)
2010  
151
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555067] Ann Oncol 21 Suppl 5(-): v15-9 (2010)
2004  
152
Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics.
[15477297] Ann Oncol 15 Suppl 4(-): iv133-8 (2004)
2010  
153
Treatment of HER2-overexpressing breast cancer.
[20943641] Ann Oncol 21 Suppl 7(-): vii36-40 (2010)
2010  
154
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
[20943632] Ann Oncol 21 Suppl 7(-): vii30-5 (2010)
2010  
155
Genetic counselling for hereditary predisposition to ovarian and breast cancer.
[20943638] Ann Oncol 21 Suppl 7(-): vii334-8 (2010)
2010  
156
What can the pathologist offer for optimal treatment choice?
[20943626] Ann Oncol 21 Suppl 7(-): vii27-9 (2010)
2010  
157
Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse.
[20943601] Ann Oncol 21 Suppl 7(-): vii103-6 (2010)
2010  
158
Benefits and adverse effects of endocrine therapy.
[20943602] Ann Oncol 21 Suppl 7(-): vii107-11 (2010)
2010  
159
Chemotherapy with or without trastuzumab.
[20943603] Ann Oncol 21 Suppl 7(-): vii112-9 (2010)
2007  
160
Recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[17491064] Ann Oncol 18 Suppl 2(-): ii9-11 (2007)
2007  
161
2009  
162
BRCA in breast cancer: ESMO clinical recommendations.
[19454451] Ann Oncol 20 Suppl 4(-): 19-20 (2009)
2009  
163
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454439] Ann Oncol 20 Suppl 4(-): 15-8 (2009)
2009  
164
Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454421] Ann Oncol 20 Suppl 4(-): 10-4 (2009)
2009  
165
Breast carcinoma--rare types: review of the literature.
[19602565] Ann Oncol 20(11): 1763-70 (2009)
2010  
166
Histological, molecular and functional subtypes of breast cancers.
[21057215] Cancer Biol Ther 10(10): 955-60 (2010)
2007  
167
MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing.
[17786032] Cancer Biol Ther 6(9): 1355-7 (2007)
2010  
168
2008  
169
2010  
170
Cystic breast masses and the ACRIN 6666 experience.
[20868895] Radiol Clin North Am 48(5): 931-87 (2010)
2010  
171
Ductal carcinoma in situ of the breast: MR imaging findings with histopathologic correlation.
[21071382] Radiographics 30(6): 1673-87 (2010)
2010  
172
Can MR Imaging contribute in characterizing well-circumscribed breast carcinomas?
[21071383] Radiographics 30(6): 1689-702 (2010)
2009  
173
Emerging technologies for assessing HER2 amplification.
[19762531] Am J Clin Pathol 132(4): 539-48 (2009)
2011  
174
Genomic testing and therapies for breast cancer in clinical practice.
[21711068] Am J Manag Care 17(5 Spec No): e174-81 (2011)
2011  
175
US insurance program's experience with a multigene assay for early-stage breast cancer.
[21711071] Am J Manag Care 17(5 Spec No): e194-202 (2011)
2006  
176
Medical treatment of early breast cancer. I: adjuvant treatment.
[16399737] BMJ 332(7532): 34-7 (2006)
2006  
177
Medical treatment of early breast cancer. IV: neoadjuvant treatment.
[16439402] BMJ 332(7535): 223-4 (2006)
2006  
178
Medical treatment of early breast cancer. III: chemotherapy.
[16424494] BMJ 332(7534): 161-2 (2006)
2008  
179
Gynaecomastia and breast cancer in men.
[18369226] BMJ 336(7646): 709-13 (2008)
2009  
180
ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.
[19527773] Biochim Biophys Acta 1796(2): 162-75 (2009)
2008  
181
Overview of breast cancer staging and surgical treatment options.
[18457192] Cleve Clin J Med 75 Suppl 1(-): S10-6 (2008)
2008  
182
Trends in breast cancer screening and diagnosis.
[18457191] Cleve Clin J Med 75 Suppl 1(-): S2-9 (2008)
2006  
183
The basal phenotype of BRCA1-related breast cancer: past, present and future.
[16687925] Cell Cycle 5(9): 963-7 (2006)
2010  
184
The Met receptor tyrosine kinase and basal breast cancer.
[20237428] Cell Cycle 9(6): 1043-50 (2010)
2010  
185
Managing aromatase inhibitors in breast cancer survivors: not just for oncologists.
[20511486] Mayo Clin Proc 85(6): 560-6; quiz 566 (2010)
2009  
186
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.
[19075184] Endocr Rev 30(1): 51-74 (2009)
2011  
187
Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients.
[22069477] PLoS One 6(11): e26946 (2011)
2010  
188
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
[20858840] Clin Cancer Res 16(19): 4702-10 (2010)
2010  
189
Metformin: a therapeutic opportunity in breast cancer.
[20215559] Clin Cancer Res 16(6): 1695-700 (2010)
2008  
190
Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.
[18281527] Clin Cancer Res 14(4): 961-70 (2008)
2010  
191
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.
[20421264] Oncologist 15(5): 457-65 (2010)
2010  
192
Review of the clinical studies using the 21-gene assay.
[20421266] Oncologist 15(5): 447-56 (2010)
2010  
193
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
[20080863] Oncologist 15(1): 26-36 (2010)
2010  
194
Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.
[20200040] Oncologist 15(3): 216-35 (2010)
2009  
195
HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.
[19684074] Oncologist 14(8): 760-8 (2009)
2008  
196
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.
[18448551] Oncologist 13(4): 373-81 (2008)
2009  
197
Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer.
[19887469] Oncologist 14(11): 1061-9 (2009)
2010  
198
Primary systemic chemotherapy for inflammatory breast cancer.
[20503414] Cancer 116(11 Suppl): 2821-8 (2010)
2010  
199
Inflammatory breast cancer--The Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007.
[20503413] Cancer 116(11 Suppl): 2815-20 (2010)
2010  
200
Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments.
[20503411] Cancer 116(11 Suppl): 2794-805 (2010)
2010  
201
Gene expression profiling of inflammatory breast cancer.
[20503410] Cancer 116(11 Suppl): 2783-93 (2010)
2010  
202
Targeted therapy in inflammatory breast cancer.
[20503407] Cancer 116(11 Suppl): 2758-9 (2010)
2010  
203
Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge.
[20503405] Cancer 116(11 Suppl): 2748-54 (2010)
2010  
204
Potential impact of tumor registry rule changes for recording inflammatory breast cancer.
[20503404] Cancer 116(11 Suppl): 2745-7 (2010)
2006  
205
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
[16770784] Cancer 107(2): 221-31 (2006)
2011  
206
Adjuvant therapy for women over age 65 with breast cancer.
[21691560] Dtsch Arztebl Int 108(21): 365-71 (2011)
2010  
207
A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
[21044553] Health Technol Assess 14(50): 1-103 (2010)
2009  
208
Lapatinib for the treatment of HER2-overexpressing breast cancer.
[19846022] Health Technol Assess 13 Suppl 3(-): 1-6 (2009)
2009  
209
Male breast cancer: experience from a Malaysian tertiary centre.
[19495524] Singapore Med J 50(5): 519-21 (2009)
2011  
210
Diagnosis and local management of breast cancer: part I.
[21823890] Future Oncol 7(8): 955-7 (2011)
2011  
211
Diagnosis and local management of breast cancer: part II.
[21823891] Future Oncol 7(8): 959-61 (2011)
2009  
212
Current role of breast duct microendoscopy in malignancy.
[20001790] Future Oncol 5(10): 1523-6 (2009)
2002  
213
Perspectives on the chemical etiology of breast cancer.
[11834470] Environ Health Perspect 110 Suppl 1(-): 119-28 (2002)
2011  
214
False-negative tests in breast cancer management.
[21934177] Neth J Med 69(7): 324-9 (2011)
2002  
215
Anti-aromatase agents in the treatment and prevention of breast cancer.
[11965225] Cancer Control 9(2 Suppl): 2-8 (2002)
2002  
216
Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
[11965226] Cancer Control 9(2 Suppl): 9-15 (2002)
2002  
217
The expanding role of epirubicin in the treatment of breast cancer.
[11965227] Cancer Control 9(2 Suppl): 16-27 (2002)
2007  
218
High-risk benign breast lesions: current strategies in management.
[17914332] Cancer Control 14(4): 321-9 (2007)
2007  
219
Management options after prophylactic surgeries in women with BRCA mutations: a review.
[17914333] Cancer Control 14(4): 330-7 (2007)
2007  
220
Breast ductal secretions: clinical features, potential uses, and possible applications.
[17914335] Cancer Control 14(4): 350-9 (2007)
2005  
221
Molecularly targeted therapies for breast cancer.
[15855890] Cancer Control 12(2): 73-81 (2005)
2010  
222
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.
[20203220] J Clin Pathol 63(3): 210-9 (2010)
2007  
223
Non-operative breast pathology: columnar cell lesions.
[17182657] J Clin Pathol 60(12): 1307-12 (2007)
2007  
224
Non-operative breast pathology: lobular neoplasia.
[17182661] J Clin Pathol 60(12): 1321-7 (2007)
2007  
225
Demystifying basal-like breast carcinomas.
[17496191] J Clin Pathol 60(12): 1328-32 (2007)
2007  
226
Non-operative breast pathology.
[18042687] J Clin Pathol 60(12): 1297-9 (2007)
2007  
227
Non-operative breast pathology: apocrine lesions.
[18042688] J Clin Pathol 60(12): 1313-20 (2007)
2010  
228
Diagnostic evaluation of papillary lesions of the breast on core biopsy.
[20473278] Mod Pathol 23(7): 1021-8 (2010)
2010  
229
Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology.
[20436497] Mod Pathol 23 Suppl 2(-): S1-7 (2010)
2010  
230
Lobular neoplasia: morphology, biological potential and management in core biopsies.
[20436498] Mod Pathol 23 Suppl 2(-): S14-25 (2010)
2010  
231
Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale.
[20436499] Mod Pathol 23 Suppl 2(-): S26-32 (2010)
2010  
232
Clinical applications of breast pathology: management of in situ breast carcinomas and sentinel node biopsy issues.
[20436500] Mod Pathol 23 Suppl 2(-): S33-5 (2010)
2010  
233
Breast core needle biopsy: issues and controversies.
[20436501] Mod Pathol 23 Suppl 2(-): S36-45 (2010)
2010  
234
Pathology of hereditary breast cancer.
[20436502] Mod Pathol 23 Suppl 2(-): S46-51 (2010)
2010  
235
Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.
[20436503] Mod Pathol 23 Suppl 2(-): S52-9 (2010)
2010  
236
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.
[20436504] Mod Pathol 23 Suppl 2(-): S60-4 (2010)
2010  
237
Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation.
[20436505] Mod Pathol 23 Suppl 2(-): S8-13 (2010)
2005  
238
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
[15933754] Mod Pathol 18(10): 1305-20 (2005)
2008  
239
Her2 cross talk and therapeutic resistance in breast cancer.
[18508484] Front Biosci 13(-): 3906-12 (2008)
2007  
240
The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.
[17673939] Mol Med 13(7-8): 396-406 (2007)
2009  
241
MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer.
[19580428] Expert Rev Mol Diagn 9(5): 423-40 (2009)
2011  
242
Unraveling the complexity of basal-like breast cancer.
[21876228] Oncotarget 2(8): 588-9 (2011)
2011  
243
A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables.
[21709316] Oncotarget 2(7): 529-37 (2011)
2011  
244
Elevated PI3K signaling drives multiple breast cancer subtypes.
[21646685] Oncotarget 2(6): 435-47 (2011)
2002  
245
Stromal effects on mammary gland development and breast cancer.
[12004111] Science 296(5570): 1046-9 (2002)
2009  
246
The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions.
[19372493] J Nucl Med 50(5): 738-48 (2009)
2009  
247
Response to therapy in breast cancer.
[19380410] J Nucl Med 50 Suppl 1(-): 55S-63S (2009)
2010  
248
The emerging role of Krüppel-like factors in endocrine-responsive cancers of female reproductive tissues.
[19833720] J Endocrinol 204(3): 223-31 (2010)
2002  
249
Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer.
[11914182] Endocr Relat Cancer 9(1): 45-59 (2002)
2002  
250
The development and clinical use of trastuzumab (Herceptin).
[12121832] Endocr Relat Cancer 9(2): 75-85 (2002)
2011  
251
Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.
[21613412] Endocr Relat Cancer 18(4): C19-24 (2011)
2011  
252
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.
[21502311] Endocr Relat Cancer 18(3): R79-89 (2011)
2011  
253
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
[21342044] Expert Rev Anticancer Ther 11(2): 263-75 (2011)
2011  
254
Targeting the leptin receptor: a potential new mode of treatment for breast cancer.
[21916566] Expert Rev Anticancer Ther 11(8): 1147-50 (2011)
2008  
255
Rational targeting of Notch signaling in breast cancer.
[18699758] Expert Rev Anticancer Ther 8(8): 1197-202 (2008)
2010  
256
Breast cancer cell dormancy in bone marrow: potential therapeutic targets within the marrow microenvironment.
[20131988] Expert Rev Anticancer Ther 10(2): 129-32 (2010)
2010  
257
Tumour suppressor function of MDA-7/IL-24 in human breast cancer.
[20735832] Cancer Cell Int 10(): 29 (2010)
2012  
258
Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo.
[22640485] J Exp Clin Cancer Res 31(1): 51 (2012)
2010  
259
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
[20520800] PLoS Med 7(5): e1000279 (2010)
2011  
260
Potential utility of natural products as regulators of breast cancer-associated aromatase promoters.
[21693041] Reprod Biol Endocrinol 9(-): 91 (2011)
2010  
261
Estrogen and xenoestrogens in breast cancer.
[19933552] Toxicol Pathol 38(1): 110-22 (2010)
2007  
262
New biomarkers in breast cancer: microRNAs and leptins--where are we now?
[20477455] Biomark Med 1(1): 9-11 (2007)
2008  
263
2002  
264
Progesterone receptors--animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer.
[12473170] Breast Cancer Res 4(6): 240-3 (2002)
2002  
265
Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.
[12473171] Breast Cancer Res 4(6): 244-8 (2002)
2002  
266
Actions of bisphosphonates in animal models of breast cancer.
[11879558] Breast Cancer Res 4(1): 35-41 (2002)
2002  
267
Progesterone receptors - animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer.
[12223121] Breast Cancer Res 4(5): 182-6 (2002)
2002  
268
The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis.
[12223124] Breast Cancer Res 4(5): 197-201 (2002)
2002  
269
Direct effects of bisphosphonates on breast cancer cells.
[11879555] Breast Cancer Res 4(1): 18-23 (2002)
2011  
270
Therapeutic targets for bone metastases in breast cancer.
[21586099] Breast Cancer Res 13(2): 207 (2011)
2011  
271
Functional magnetic resonance: biomarkers of response in breast cancer.
[21392409] Breast Cancer Res 13(1): 204 (2011)
2011  
272
Gene signatures of breast cancer progression and metastasis.
[21345283] Breast Cancer Res 13(1): 201 (2011)
2004  
273
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy.
[14680484] Breast Cancer Res 6(1): 39-52 (2004)
2003  
274
The diagnosis and management of pre-invasive breast disease--current challenges, future hopes.
[12927033] Breast Cancer Res 5(5): 248-9 (2003)
2003  
275
The diagnosis and management of pre-invasive breast disease: radiological diagnosis.
[12927034] Breast Cancer Res 5(5): 250-3 (2003)
2003  
276
The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
[12927035] Breast Cancer Res 5(5): 254-7 (2003)
2003  
277
The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ.
[12927036] Breast Cancer Res 5(5): 258-62 (2003)
2003  
278
The diagnosis and management of pre-invasive breast disease: flat epithelial atypia--classification, pathologic features and clinical significance.
[12927037] Breast Cancer Res 5(5): 263-8 (2003)
2003  
279
The diagnosis and management of pre-invasive breast disease: pathological diagnosis--problems with existing classifications.
[12927038] Breast Cancer Res 5(5): 269 (2003)
2003  
280
Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development.
[12631389] Breast Cancer Res 5(2): 101-6 (2003)
2010  
281
Breast cancer metastasis to the bone: mechanisms of bone loss.
[21176175] Breast Cancer Res 12(6): 215 (2010)
2010  
282
Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression.
[20594364] Breast Cancer Res 12(3): 206 (2010)
2010  
283
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.
[21050423] Breast Cancer Res 12 Suppl 2(-): S2 (2010)
2010  
284
Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts.
[20398329] Breast Cancer Res 12(2): 202 (2010)
2010  
285
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
[20459590] Breast Cancer Res 12(2): 203 (2010)
2010  
286
Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors.
[20497549] Breast Cancer Res 12(3): R29 (2010)
2010  
287
Tumour-associated carbohydrate antigens in breast cancer.
[20550729] Breast Cancer Res 12(3): 204 (2010)
2009  
288
Epithelial to mesenchymal transition and breast cancer.
[19909494] Breast Cancer Res 11(6): 213 (2009)
2008  
289
PGRMC1: a new biomarker for the estrogen receptor in breast cancer.
[19090968] Breast Cancer Res 10(6): 113 (2008)
2008  
290
Fatal attraction: why breast cancer cells home to bone.
[18226190] Breast Cancer Res 10(1): 101 (2008)
2009  
291
Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells.
[19996302] Mol Cancer Res 7(12): 2000-10 (2009)
2011  
292
High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters.
[22178934] Cell Physiol Biochem 28(5): 813-22 (2011)
2012  
293
Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor negative breast cancer.
[22807578] Mol Cancer Ther (): (2012)
2008  
294
The role of TRPV6 in breast carcinogenesis.
[18245667] Mol Cancer Ther 7(2): 271-9 (2008)
2007  
295
Brain metastases from breast cancer: management approach.
[18079579] J Cancer Res Ther 3(3): 157-65 (2007)
2010  
296
Advantages of Ductal Echography (DE) over conventional breast investigation in the diagnosis of breast malignancies.
[21165452] Med Ultrason 12(1): 32-42 (2010)
2011  
297
Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres.
[21655158] Curr Oncol 18(3): 119-25 (2011)
2011  
298
Triple-negative breast cancers: an updated review on treatment options.
[21874107] Curr Oncol 18(4): e173-9 (2011)
2011  
299
Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.
[21874117] Curr Oncol 18(4): 180-90 (2011)
2011  
300
A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis.
[21874118] Curr Oncol 18(4): 191-6 (2011)
2010  
301
Endocrine therapy for male breast cancer: rates of toxicity and adherence.
[20975874] Curr Oncol 17(5): 17-21 (2010)
2008  
302
A primer of bone metastases management in breast cancer patients.
[18231649] Curr Oncol 15(Suppl 1): S50-7 (2008)
2010  
303
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
[20404251] J Clin Oncol 28(16): 2784-95 (2010)
2009  
304
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
[19470930] J Clin Oncol 27(19): 3235-58 (2009)
2010  
305
Inflammatory breast cancer: the disease, the biology, the treatment.
[20959401] CA Cancer J Clin 60(6): 351-75 (2010)
2008  
306
The sea of uncertainty surrounding ductal carcinoma in situ--the price of screening mammography.
[18270336] J Natl Cancer Inst 100(4): 228-9 (2008)
2011  
307
Diffuse infiltrative lesion of the breast: clinical and radiologic features.
[21228947] Korean J Radiol 12(1): 113-21 (2011)
2007  
308
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
[17892469] Int J Clin Pract 61(12): 2051-63 (2007)
2010  
309
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.
[20101445] J Mammary Gland Biol Neoplasia 15(1): 35-47 (2010)
2010  
310
Breast cancer epigenetics: from DNA methylation to microRNAs.
[20101446] J Mammary Gland Biol Neoplasia 15(1): 5-17 (2010)
2007  
311
Metastasis suppressors and their roles in breast carcinoma.
[17587154] J Mammary Gland Biol Neoplasia 12(2-3): 175-90 (2007)
2009  
312
Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer?
[19350209] J Mammary Gland Biol Neoplasia 14(2): 145-57 (2009)
2009  
313
Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression.
[19396528] J Mammary Gland Biol Neoplasia 14(2): 131-44 (2009)
2008  
314
The contribution of growth hormone to mammary neoplasia.
[18253708] J Mammary Gland Biol Neoplasia 13(1): 131-45 (2008)
2011  
315
Bevacizumab in metastatic breast cancer: when may it be used?
[21789158] Ther Adv Med Oncol 3(2): 85-93 (2011)
2008  
316
Arzoxifene: the evidence for its development in the management of breast cancer.
[21221190] Core Evid 2(4): 251-8 (2008)
2009  
317
Non-epithelial malignancies and metastatic tumours of the breast.
[19568446] Ulster Med J 78(2): 105-12 (2009)
2002  
318
Antiaromatase agents: evolving role in adjuvant therapy.
[12020394] Clin Breast Cancer 3(1): 33-42 (2002)
2008  
319
Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
[19073502] Clin Breast Cancer 8(6): 487-92 (2008)
2009  
320
Enhancing the efficacy of hormonal agents with selected targeted agents.
[19561004] Clin Breast Cancer 9 Suppl 1(-): S28-36 (2009)
2009  
321
A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
[19561006] Clin Breast Cancer 9 Suppl 1(-): S6-S17 (2009)
2009  
322
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
[19596646] Clin Breast Cancer 9 Suppl 2(-): S73-81 (2009)
2009  
323
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
[19561003] Clin Breast Cancer 9 Suppl 1(-): S18-27 (2009)
2008  
324
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.
[18621608] Clin Breast Cancer 8(2): 124-33 (2008)
2009  
325
Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.
[20360896] Int J Gen Med 2(-): 129-40 (2009)
2011  
326
Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.
[21552384] J Cancer 2(-): 232-61 (2011)
2010  
327
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
[21037871] J Oncol Pract 6(4): 195-7 (2010)
2010  
328
Breast cancer as an infectious disease.
[20088725] Womens Health (Lond Engl) 6(1): 5-8 (2010)
2010  
329
A rare tumour of the breast: carcinosarcoma.
[21811528] J Clin Med Res 2(2): 96-8 (2010)
2011  
330
Sonographic findings of additional malignant lesions in breast carcinoma seen by second look ultrasound.
[21966631] J Clin Imaging Sci 1(-): 34 (2011)
2009  
331
The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer.
[19418218] Breast Cancer Res Treat 116(2): 225-37 (2009)
2008  
332
An overview of prognostic factors for long-term survivors of breast cancer.
[17377838] Breast Cancer Res Treat 107(3): 309-30 (2008)
2010  
333
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
[20886213] Cancer Chemother Pharmacol 66(6): 1005-12 (2010)
2010  
334
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
[20524868] Arch Pathol Lab Med 134(6): 907-22 (2010)
2011  
335
Pathology of hereditary breast cancer.
[21336636] Cell Oncol (Dordr) 34(2): 71-88 (2011)
2011  
336
Myofibroblastoma of the breast: Case report and literature review.
[22096693] Int J Surg Case Rep 2(6): 93-6 (2011)
2011  
337
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.
[22109790] J Community Genet 2(2): 53-69 (2011)
2004  
338
DNA double strand break repair and its association with inherited predispositions to breast cancer.
[20233482] Hered Cancer Clin Pract 2(1): 37-43 (2004)
2011  
339
The 70-gene prognostic signature for korean breast cancer patients.
[21847392] J Breast Cancer 14(1): 33-8 (2011)
2008  
340
Epigenetic gene silencing in the Wnt pathway in breast cancer.
[18398311] Epigenetics 3(2): 59-63 (2008)
2008  
341
Matrix-producing mammary carcinoma: a rare breast tumor.
[18603703] Indian J Pathol Microbiol 51(2): 263-4 (2008)
2008  
342
Progesterone receptor isoform functions in normal breast development and breast cancer.
[18197783] Crit Rev Eukaryot Gene Expr 18(1): 11-33 (2008)
2011  
343
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.
[21569417] J Exp Clin Cancer Res 30(-): 54 (2011)
2008  
344
ERbeta in breast cancer--onlooker, passive player, or active protector?
[18501937] Steroids 73(11): 1039-51 (2008)
2011  
345
Breast cancer at bone metastatic sites: recent discoveries and treatment targets.
[21484191] J Cell Commun Signal 5(2): 85-99 (2011)
2010  
346
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.
[21081926] Br J Cancer 103(12): 1788-93 (2010)
2011  
347
Triple negative breast cancer: unmet medical needs.
[21161370] Breast Cancer Res Treat 125(3): 627-36 (2011)
2010  
348
Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer.
[20700648] Breast Cancer Res Treat 124(3): 863-73 (2010)
2010  
349
Strut-adjusted volume implant: a targeted radiation treatment in breast cancer.
[21142853] Future Oncol 6(12): 1813-6 (2010)
2010  
350
Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer.
[21161341] J Mammary Gland Biol Neoplasia 15(4): 389-97 (2010)
2010  
351
EGFR signaling in breast cancer: bad to the bone.
[20813200] Semin Cell Dev Biol 21(9): 951-60 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia